Physician profile
Keith S Leibowitz
NPI 1134190903
$2,688.46
in general payments reported to CMS, 2019-2025
31 companies · $562 in 2025
The $562 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $580 · 2020: $85.02 · 2021: $38.71 · 2022: $369 · 2023: $560 · 2024: $493 · 2025: $562.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,615.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,615.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $397.76 | 2019-2025 | |
| Amgen INC. | $280.86 | 2019-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $253.24 | 2019-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $161.79 | 2019-2024 | Lifevest |
| Merck Sharp & Dohme LLC | $151.45 | 2022-2024 | Verquvo |
| Janssen Pharmaceuticals, INC | $137.83 | 2019-2024 | Xarelto |
| Amarin Pharma, INC. | $119.38 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $98.01 | 2019-2024 | |
| Baxter Healthcare | $92.16 | 2023-2025 | Hillrom - Cardiac Ambulatory Monitor |
| Cvrx, INC. | $90.00 | 2024-2025 | Barostim Neo System |
| Novo Nordisk INC | $88.95 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Boston Scientific Corporation | $79.41 | 2022-2024 | Watchman Flx |
| E.R. Squibb & Sons, L.L.C. | $77.56 | 2019-2025 | Camzyos, Eliquis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $74.65 | 2019-2023 | Jardiance |
| Irhythm Technologies, INC. | $68.88 | 2021-2024 | Zio Monitor, Zio Xt Patch |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $68.12 | 2019-2023 | Cardiomems |
| Bayer Healthcare Pharmaceuticals INC. | $57.88 | 2023-2025 | |
| Heartflow, INC. | $47.26 | 2023 | Ffrct |
| Esperion Therapeutics, INC. | $45.63 | 2022-2025 | Nexletol |
| Philips North America LLC | $44.81 | 2025 | Mcot |
| Impulse Dynamics (USA) INC. | $38.54 | 2022-2023 | Optimizer |
| Kiniksa Pharmaceuticals International, Plc | $36.74 | 2024 | Arcalyst |
| Astrazeneca Pharmaceuticals LP | $27.89 | 2023 | Farxiga |
| Regeneron Healthcare Solutions, INC. | $23.81 | 2019 | |
| Kestra Medical Technology Services, INC. | $20.34 | 2024 | Assure Wcd |
| Bridgebio Pharma, INC. | $19.00 | 2025 | Attruby |
| Glaxosmithkline, LLC. | $18.85 | 2025 | Shingrix, Arexvy |
| Medicomp INC | $17.80 | 2024 | Telepatch Cardiac Monitor |
| Daiichi Sankyo INC. | $17.00 | 2023 | Injectafer |
| Kowa Pharmaceuticals America, INC. | $16.92 | 2024 | Livalo |
| Kiniksa Pharmaceuticals, LTD. | $15.94 | 2023 | Arcalyst |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Keith Leibowitz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.